October 29, 2025

FDA Pushes Faster, Cheaper Route for Biosimilar Approval

The FDA released new draft guidance to streamline biosimilar development.

Conexiant

October 29, 2025

Can SGLT-2 Inhibitors Shield Against Autoimmune Disease?

Researchers found sodium-glucose cotransporter-2 inhibitors lowered autoimmune rheumatic disease risk by 11% in adults with type 2 diabetes.

Conexiant

October 29, 2025

Stable Rates Found in Childhood Type 2 Diabetes

5-year survey outlines social patterns in US pediatric patients with type 2 diabetes.

Conexiant

October 29, 2025

Could the Way You Walk Change Outcomes?

Researchers find that the duration of walking bouts—not just total daily steps—predicts long-term cardiovascular and mortality risk.

Conexiant

October 29, 2025

H-1B Visa Changes: Who Pays the Price?

New fee structure could hit hardest where physicians are needed most.

Conexiant

October 28, 2025

Fewer Loans: Fewer Doctors?

Changes to federal student loan policy reintroduce borrowing caps for graduate and professional education, impacting how future physicians finance medical training.

KFF Health News

October 27, 2025

How Hormones May Influence Tirzepatide Outcomes

Researchers show how reproductive stage and hormone therapy influence weight-loss outcomes in women treated with tirzepatide.

Conexiant

October 27, 2025

Why Open Access May Not Boost Citations

Researchers found that companion open access journals charge high publication fees yet yield fewer citations than traditional journals.

Conexiant

October 24, 2025

Elinzanetant Approved for Menopausal Hot Flashes by FDA

Bayer’s dual neurokinin 1 and 3 receptor antagonist elinzanetant (Lynkuet) reduced the frequency and severity of menopausal vasomotor symptoms in phase 3 OASIS trials, providing a once daily, nonhormonal treatment option for moderate to severe hot flashes.

Conexiant